At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Trading 07-15 11:47:24 EDT
541.50
+4.64
+0.86%
High544.27Low529.75Vol59.78K
Open536.05D1 Closing536.86Amplitude2.70%
Mkt Cap12.48BTradable Cap7.58BTotal Shares23.06M
T/O32.26MT/O Rate0.43%Tradable Shares14.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)
TIPRANKS  ·  07-14 21:01
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)
TIPRANKS  ·  07-14 20:40
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)
Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says
MT Newswires Live  ·  07-14 02:56
Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says
Madrigal Wins Three New US Patents for MASH Drug Rezdiffra, Boosting IP Protection
Reuters  ·  07-13 20:04
Madrigal Wins Three New US Patents for MASH Drug Rezdiffra, Boosting IP Protection
Madrigal Grants New Hires 604 Stock Options, 2,952 Restricted Stock Units Under Inducement Plan
Reuters  ·  07-07
Madrigal Grants New Hires 604 Stock Options, 2,952 Restricted Stock Units Under Inducement Plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  07-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  07-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative
Simply Wall St.  ·  07-04
Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative
Suzhou Ribo Hits First Milestone in Madrigal Sirna Collaboration for MASH Drug Candidate
Reuters  ·  07-02
Suzhou Ribo Hits First Milestone in Madrigal Sirna Collaboration for MASH Drug Candidate
Medicare Coverage Could Put These Obesity Drug Stocks In Focus
Simply Wall St.  ·  06-30
Medicare Coverage Could Put These Obesity Drug Stocks In Focus
Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan
Reuters  ·  06-23
Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-23
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-23
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1
Reuters  ·  06-18
Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
Dow Jones  ·  06-11
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550
MT Newswires Live  ·  06-11
BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Simply Wall St.  ·  06-06
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan
Reuters  ·  06-05
Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--